Therapeutic effect and mechanism of Bairui granules against influenza virus-induced viral pneumonia in mice

doi:10.19803/j.1672-8629.20230321

Abstract

Abstract: Objective To study the therapeutic effect and mechanism of Bairui granules against influenza virus-induced viral pneumonia in mice. Methods According to body weight, ICR mice were randomly divided into groups: the normal control group, model control group, Bairui granules 18.84、9.42、4.71 g·kg^-1 groups, and the positive control oseltamivir phosphate capsule group. Except the normal control group, all these groups of mice were intranasally infected with influenza virus to establish a mouse model of viral pneumonia. The survival and mortality of the mice were observed. Furthermore, the body weight, lung index, viral load in lung tissue, and serum levels of inflammatory factors interleukin-6 (IL-6), γ-interferon (IFN-γ), and tumor necrosis factor-α (TNF-α) at 3, 5 and 7 days post infection (dpi) were measured in the normal control group, model control group, Bairui granules 18.84 g·kg^-1 group and oseltamivir phosphate capsule group. Results Compared with the normal control group, the mice infected with influenza A virus showed a decrease in weight but an increase in the lung index, viral load in lung tissue, and the levels of serum inflammatory factors, indicating that a mouse model for influenza virus pneumonia was established. Compared with the model control group, the Bairui granules 18.84, 9.42, 4.71 g·kg^-1 groups showed a significant prolongation in survival time (P<0.01) and a significant decrease in mortality after being infected by influenza virus (P<0.01). In addition, the Bairui granules 18.84 g·kg^-1 group exhibited a significant increase in body weight (P<0.05) at 5 and 7 dpi, and a significant decrease in the lung index (P<0.05) at 3,5 and 7 dpi. Moreover, the viral load in the Bairui granules 18.84 g·kg^-1group was significantly lower than that of the model control group (P<0.01) at 5 dpi, and the serum IL-6 content in the Bairui granules 18.84 g·kg^-1 group was significantly lower than that of the model control group (P<0.01) at 7 dpi. Conclusion Bairui granules show some therapeutic effect against viral pneumonia in mice induced by influenza virus infection by increasing body weight, decreasing the lung index, prolonging survival, and reducing mortality in virus-infected mice.

Key words: Bairui granules, influenza virus pneumonia, death protection, inflammatory factors, viral load, mice

CLC Number:

R971
R744

DENG Yurong, SUN Jianhui, HAO Liyu, SHAN Zhongchao, YU Zeyue, LI Jianliang, HUO Hairu, LI Qijing, ZHANG Hongmeng, LI Hongmei. Therapeutic effect and mechanism of Bairui granules against influenza virus-induced viral pneumonia in mice[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1249-1255.

References

[1] CACERES CJ, SEIBERT B, CARGNIN FF, et al.Influenza antivirals and animal models[J]. FEBS Open Bio, 2022, 12(6): 1142-1165.
[2] KISSLING E, ROSE A, EMBORG HD, et al.Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019[J]. Euro Surveill,2019,24(8):1900121.
[3] YI N.Advances in anti-influenza virus effects of traditional Chinese medicine[J]. Heilongjiang Medicine Journal(黑龙江医药), 2021, 34(2): 306-308.
[4] LIAO YY, ZHOU GQ.Research progress in clinical application of Bailui granules[J]. Journal of Modern Medicine & Health(现代医药卫生), 2021, 37(7): 1149-1152.
[5] ZHU MW, MA WX.Therapeutic effect of Bailiu granules combined with ribavirin in the treatment of seasonal influenza in children[J]. China Pharmacist(中国药师), 2015, 18(8): 1343-1345.
[6] PAN YP.Effect of oseltamivir phosphate combined with Balui granules in the treatment of influenza in children[J]. Strait Pharmaceutical Journal(海峡药学), 2021, 33(8): 113-115.
[7] CHEN Q.Research Methodology of TCM Pharmacology(中药药理研究方法学)[M]. Beijing: People’s Medical Publishing House, 2006.
[8] SUN JH, TANG CY, HUO HR, et al.Protective effect of Houyanqing extract on pneumonia mice model infected with influenza virus[J]. Central South Pharmacy(中南药学), 2019, 17(8): 1229-1233.
[9] MENG QY.Basic Theoretical Research Methods and Experimental techniques of Integrated Chinese and Western Medicine[M]. Beijing: Ancient Books of Traditional Chinese Medicine Publishing House, 1999.
[10] BAO L, GENG ZH, GUO SS, et al.Effect of Reyanning Heji on animal models of respiratory infectious inflammation[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(3): 241-247.
[11] YAO RM, MAO X, QU TG, et al.Effect of Chuankezhi injection on prevention and treatment of H1N1 influenza virus in mice[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2019, 25(12): 43-49.
[12] LI Z, LI L, ZHAO S, et al.Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies[J]. Journal of Thoracic Disease, 2018, 10(Suppl 19): 2248-2259.
[13] GIANNELLA M, ALONSO M, GARCIA DE VD, et al.Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients[J]. Clinical Microbiology and Infection, 2011, 17(8): 1160-1165.
[14] SONG LS, ZHANG XM, GUO QS, et al.Study on winter dormancy of Thesium chinense and its phenological phase[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2015, 40(23): 4585-4590.
[15] ZOU Y, HONG M, YANG XF.Isolation of chemical components from thesium Chinense[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2016, 22(7): 74-77.
[16] CHEN PY, CHEN XQ, WU C, et al.Research on development and utilization of thesium Chinense turcz[J]. Chinese Wild Plant Resources(中国野生植物资源), 2020, 39(6): 48-52.
[17] GUO AL, ZHU WW, ZHU J, et al.Clinical observation on the treatment for bronchiolitis in children with Bairui granules and atomization[J]. Chinese Pediatrics of Integrated Traditional and Western Medicine(中国中西医结合儿科学),2017, 9(1): 46-48.
[18] MURDACA G, PALADIN F, TONACCI A, et al.The potential role of cytokine storm pathway in the clinical course of viral respiratory pandemic[J]. Biomedicines, 2021, 9(11): 1688.
[19] LIU Q, ZHOU Y, YANG Z.The cytokine storm of severe influenza and development of immunomodulatory therapy[J]. Cellular & Molecular Immunology, 2016, 13(1): 3-10.
[20] BERMEJO-MARTIN JF, ORTIZ DE LR, PUMAROLA T, et al.Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza[J]. Critical Care (London, England), 2009, 13(6): R201.
[21] BETAKOVA T, KOSTRABOVA A, LACHOVA V, et al.Cytokines induced during influenza virus infection[J]. Current Pharmaceutical Design, 2017, 23(18): 2616-2622.
[22] PANDEY P, KARUPIAH G.Targeting tumour necrosis factor to ameliorate viral pneumonia[J]. The FEBS Journal, 2022, 289(4): 883-900.
[23] PEPER RL, VAN CAMPEN H.Tumor necrosis factor as a mediator of inflammation in influenza a viral pneumonia[J]. Microbial Pathogenesis, 1995, 19(3): 175-183.
[24] FRITZ RS, HAYDEN FG, CALFEE DP, et al.Nasal cytokine and chemokine responses in experimental influenza a virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment[J]. The Journal of Infectious Diseases, 1999, 180(3): 586-593.
[25] HAGAU N, SLAVCOVICI A, GONGANAU DN, et al.Clinical aspects and cytokine response in severe H1N1 influenza a virus infection[J]. Critical Care (London, England), 2010, 14(6): R203.